Candriam S.C.A. Morpho Sys Ag Transaction History

Candriam S.C.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$4.51 - $7.39 $950,103 - $1.56 Million	-210,666 Reduced 78.36%	58,169 $281,000
Q1 2022 May 13, 2022	SELL	$5.87 - $9.73 $29,350 - $48,650	-5,000 Reduced 1.83%	268,835 $1.82 Million
Q4 2021 Feb 10, 2022	BUY	$9.08 - $12.45 $45,400 - $62,250	5,000 Added 1.86%	273,835 $7.71 Million
Q2 2021 Jul 20, 2021	SELL	$18.95 - $23.95 $239,641 - $302,871	-12,646 Reduced 4.49%	268,835 $5.18 Million
Q1 2021 Apr 29, 2021	SELL	$21.56 - $30.66 $107 - $153	-5 Reduced -0.0%	281,481 $7.66 Million

Q4 2020 Jan 22, 2021	SELL	$24.81 - $30.33 $550,682 - $673,204	-22,196 Reduced 7.31%	281,486 $7.98 Million
Q3 2020 Oct 19, 2020	BUY	$30.28 - $35.72 $1.12 Million - $1.32 Million	36,932 Added 13.85%	303,682 $9.53 Million
Q2 2020 Jul 23, 2020	BUY	$24.08 - $33.35 $3.83 Million - $5.3 Million	159,044 Added 147.66%	266,750 $8.45 Million
Q1 2020 May 26, 2020	BUY	$18.86 - $37.36 $1,603 - $3,175	85 Added 0.08%	107,706 $3.76 Million
Q4 2019 Jan 21, 2020	BUY	$26.07 - $36.32 $2.81 Million - $3.91 Million	107,621 New	107,621 $4,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.47B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.